ATRC vs. TFX, ITGR, IART, ATEC, OFIX, SRDX, ANGO, ARAY, RMTI, and RSLS
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry.
AtriCure vs.
Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Teleflex has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
In the previous week, Teleflex had 11 more articles in the media than AtriCure. MarketBeat recorded 17 mentions for Teleflex and 6 mentions for AtriCure. Teleflex's average media sentiment score of 0.81 beat AtriCure's score of 0.79 indicating that Teleflex is being referred to more favorably in the media.
Teleflex has a net margin of 7.85% compared to AtriCure's net margin of -9.61%. Teleflex's return on equity of 14.19% beat AtriCure's return on equity.
AtriCure received 44 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 69.51% of users gave AtriCure an outperform vote while only 58.64% of users gave Teleflex an outperform vote.
Teleflex presently has a consensus target price of $182.63, suggesting a potential upside of 29.18%. AtriCure has a consensus target price of $51.56, suggesting a potential upside of 48.34%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Teleflex.
95.6% of Teleflex shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 3.2% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Teleflex and AtriCure tied by winning 9 of the 18 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
AtriCure Competitors List
Related Companies and Tools
This page (NASDAQ:ATRC) was last updated on 3/25/2025 by MarketBeat.com Staff